Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

Fabhalta, a therapy for a rare blood disease, earned the green light in 2023, while Vanrafia, a medicine for a kidney disease, did so just this month. Novartis' deep pipeline will lead to more ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. The Big Pharma company discontinued the study testing intra ...

Novartis NVS shares ended the last trading session 4% higher at $107.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...

Having a child recipient and helping someone in need – especially if they knew them – were among the top reasons that people ...

Besides, Novartis, Johnson & Johnson plans to spend $55 billion over four years on domestic manufacturing, research and technology. Merck announced plans to spend $1 billion on a vaccine ...